Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
EO2401 is a cancer vaccine comprising microbiome-derived peptides that are similar to IL13Ralpha2, BIRC5, and FOXM1, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2034-2034).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Bevacizumab + EO2401 + Nivolumab||Bevacizumab EO2401 Nivolumab||0||0|
|EO2401 + Nivolumab||EO2401 Nivolumab||0||1|